{"disease":{"id":"uterine-corpus-sarcoma","name":"uterine corpus sarcoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05049538","title":"Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03914612","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":813,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05646316","title":"Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT00977574","title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":349,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04634617","title":"Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":310,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03660826","title":"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":288,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03422198","title":"Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"University of Utah","has_results":true},{"nct_id":"NCT04214067","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":164,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02601209","title":"Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":151,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01935934","title":"Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03367741","title":"Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":82,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05432791","title":"Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04200443","title":"Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04704661","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02020707","title":"Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01168232","title":"Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05691504","title":"Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01533207","title":"Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":true},{"nct_id":"NCT00478426","title":"Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03120624","title":"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03552471","title":"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03880019","title":"A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02428192","title":"Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01958580","title":"Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery","phase":"NA","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":true},{"nct_id":"NCT04906382","title":"Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Floor Backes, MD","has_results":false},{"nct_id":"NCT03902379","title":"Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}